Summarizing historical information on controls in clinical trials - PubMed (original) (raw)
Summarizing historical information on controls in clinical trials
Beat Neuenschwander et al. Clin Trials. 2010 Feb.
Abstract
Background: Historical information is always relevant when designing clinical trials, but it might also be incorporated in the analysis. It seems appropriate to exploit past information on comparable control groups.
Purpose: Phase IV and proof-of-concept trials are used to discuss aspects of summarizing historical control data as prior information in a new trial. The importance of a fair assessment of the similarity of control parameters is emphasized.
Methods: The methodology is meta-analytic-predictive. Heterogeneity of control parameters is expressed via the between-trial variation, which is the key parameter determining the prior effective sample size and its upper bound (prior maximum sample size).
Results: For a Phase IV trial (930 control patients in 11 historical trials) between-trial heterogeneity was fairly small, resulting in a prior effective sample size of approximately 90 patients. For a proof-of-concept trial (363 patients in four historical trials) heterogeneity was moderate to substantial, resulting in a prior effective sample size of approximately 20. For another proof-of-concept trial (14 patients in one historical trial), assuming substantial heterogeneity implied a prior effective sample size of 7. The prior effective sample size can only be large if the amount of historical data is large and between-trial heterogeneity is small. The prior effective sample size is bounded by the prior maximum sample size (ratio of within- to between-trial variance), irrespective of the amount of historical data.
Limitations: The meta-analytic-predictive approach assumes exchangeability of control parameters across trials. Due to the difficulty to quantify between-trial variability, sensitivity of conclusions regarding assumptions and type of inference should be assessed.
Conclusions: The use of historical control information is a valuable option and may lead to more efficient clinical trials. The proposed approach is attractive for nonconfirmatory trials, but under certain circumstances extensions to the confirmatory setting could be envisaged as well.
Similar articles
- Using historical control information for the design and analysis of clinical trials with overdispersed count data.
Gsteiger S, Neuenschwander B, Mercier F, Schmidli H. Gsteiger S, et al. Stat Med. 2013 Sep 20;32(21):3609-22. doi: 10.1002/sim.5851. Epub 2013 May 31. Stat Med. 2013. PMID: 23722585 - Bayesian semiparametric meta-analytic-predictive prior for historical control borrowing in clinical trials.
Hupf B, Bunn V, Lin J, Dong C. Hupf B, et al. Stat Med. 2021 Jun 30;40(14):3385-3399. doi: 10.1002/sim.8970. Epub 2021 Apr 13. Stat Med. 2021. PMID: 33851441 - Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H, Gsteiger S, Roychoudhury S, O'Hagan A, Spiegelhalter D, Neuenschwander B. Schmidli H, et al. Biometrics. 2014 Dec;70(4):1023-32. doi: 10.1111/biom.12242. Epub 2014 Oct 29. Biometrics. 2014. PMID: 25355546 - Incorporation of historical data in the analysis of randomized therapeutic trials.
Rietbergen C, Klugkist I, Janssen KJ, Moons KG, Hoijtink HJ. Rietbergen C, et al. Contemp Clin Trials. 2011 Nov;32(6):848-55. doi: 10.1016/j.cct.2011.06.002. Epub 2011 Jun 25. Contemp Clin Trials. 2011. PMID: 21729767 Review. - Use of historical control data for assessing treatment effects in clinical trials.
Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, Hobbs B, Ibrahim JG, Kinnersley N, Lindborg S, Micallef S, Roychoudhury S, Thompson L. Viele K, et al. Pharm Stat. 2014 Jan-Feb;13(1):41-54. doi: 10.1002/pst.1589. Epub 2013 Aug 5. Pharm Stat. 2014. PMID: 23913901 Free PMC article. Review.
Cited by
- Using historical data to facilitate clinical prevention trials in Alzheimer disease? An analysis of longitudinal MCI (mild cognitive impairment) data sets.
Berres M, Monsch AU, Spiegel R. Berres M, et al. Alzheimers Res Ther. 2021 May 7;13(1):97. doi: 10.1186/s13195-021-00832-5. Alzheimers Res Ther. 2021. PMID: 33962665 Free PMC article. - Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.
Hobbs BP, Sargent DJ, Carlin BP. Hobbs BP, et al. Bayesian Anal. 2012 Aug 28;7(3):639-674. doi: 10.1214/12-BA722. Bayesian Anal. 2012. PMID: 24795786 Free PMC article. - Measuring the effects of a personalized music intervention on agitated behaviors among nursing home residents with dementia: design features for cluster-randomized adaptive trial.
McCreedy EM, Gutman R, Baier R, Rudolph JL, Thomas KS, Dvorchak F, Uth R, Ogarek J, Mor V. McCreedy EM, et al. Trials. 2021 Oct 7;22(1):681. doi: 10.1186/s13063-021-05620-y. Trials. 2021. PMID: 34620193 Free PMC article. - A Tutorial on Modern Bayesian Methods in Clinical Trials.
Muehlemann N, Zhou T, Mukherjee R, Hossain MI, Roychoudhury S, Russek-Cohen E. Muehlemann N, et al. Ther Innov Regul Sci. 2023 May;57(3):402-416. doi: 10.1007/s43441-023-00515-3. Epub 2023 Apr 20. Ther Innov Regul Sci. 2023. PMID: 37081374 Free PMC article. - Bayesian hierarchical modeling based on multisource exchangeability.
Kaizer AM, Koopmeiners JS, Hobbs BP. Kaizer AM, et al. Biostatistics. 2018 Apr 1;19(2):169-184. doi: 10.1093/biostatistics/kxx031. Biostatistics. 2018. PMID: 29036300 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous